Matilla, Lara
Martín-Núñez, Ernesto
Garaikoetxea, Mattie
Navarro, Adela
Tamayo, Ibai
Fernández-Celis, Amaya
Gainza, Alicia
Fernández-Irigoyen, Joaquín
Santamaría, Enrique
Muntendam, Pieter
Álvarez, Virginia
Sádaba, Rafael
Jover, Eva
López-Andrés, Natalia http://orcid.org/0000-0003-3728-2606
Funding for this research was provided by:
Departamento de Salud, Gobierno de Navarra (GNa01/21)
Instituto de Salud Carlos III (FI19/00302, CD19/00251)
Universidad de La Laguna (ULL-MS-P14)
Universidad Pública de Navarra
Article History
Received: 20 July 2023
Accepted: 10 October 2023
First Online: 24 October 2023
Declarations
:
: The study protocol was approved by The Institutional Human Research Committee (Comité Ético de Experimentación Clínica. Gobierno de Navarra, Departamento de Salud) approved the study protocols (Ethics numbers 17/2013 and PI2019/59) that were performed in accordance to the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients involved in the stud.
: Not applicable.
: NLA and PM report shareholder interest in G3-Pharmaceuticals. PM reports having received remuneration from G3-Pharmaceuticals.